Treatment Algorithms: Dyslipidemia – Statin monotherapies dominate the market but uncontrolled lipid levels remain an issue

Datamonitor estimates the antidyslipidemic drug-treated population at 73.5 million patients across the seven major markets, with the majority having high cholesterol as opposed to hypertriglyceridemia alone. Statins are the dominant treatment for high cholesterol while fibrates are more used for hypertriglyceridemia. Lipid control is an unmet need in a high proportion of drug-treated patients.

Features and benefits

• Follow patient segmentation and treatment pathways for dyslipidemia across the seven major markets.
• Gain insight into the most commonly used therapies for pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia.
• Understand prescribing trends and their affect on treatment regimens.
• Identify unmet needs, especially within dyslipidemic sub-populations, which represent market opportunities.
• Understand the impact of generic entry on the antidyslipidemic market.

Highlights

Not all patients are available for drug therapy due to the low diagnosis rate, low compliance rates, and therapeutic lifestyle management as the first line of treatment. Only 43% of dyslipidemia patients are reported diagnosed within the seven major markets.

The type of dyslipidemia that a patient is diagnosed with impacts on the treatment regimen used. Statin monotherapy dominates where the target lipid is low-density lipoprotein cholesterol. This is due to statins’ superior proven efficacy in lowering both target lipid levels and cardiovascular disease risk.

Get Your Copy of Report @ http://www.reportsnreports.com/reports/160352-treatment-algorithms-dyslipidemia-statin-monotherapies-dominate-the-market-but-uncontrolled-lipid-levels-remain-an-issue.html 

Report Details :
Published: May 2012
No. of Pages: 69
 Price: Single User License: US $ 7600 Corporate User License : US $ 17000

    

Table Of Contents

OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Datamonitor key findings
Related reports

TREATMENT ALGORITHMS AND PATIENT PROFILES
Methodology
Patient profiles: seven major markets
Treatment algorithm: seven major markets

DISEASE DEFINITION AND DIAGNOSIS
Disease definition
Etiology
Lifestyle is the most common cause of dyslipidemia
Prognosis
Dyslipidemia is generally asymptomatic, but it can lead to symptomatic cardiovascular disease
Presentation and diagnosis
As an asymptomatic disease, country-wide screening is recommended to limit cardiovascular risk
Over half of dyslipidemia patients are undiagnosed
Treatment rates
Lifestyle management effectiveness is limited by under-prescription and low compliance
Variations in treatment guidelines affect reported treatment rates
Reported compliance rates vary considerably across the seven major markets

PATIENT SEGMENTATION
Segmentation by lipid levels
Pure hypertriglyceridemia is less common than cholesterol-related dyslipidemias
High-density lipoprotein cholesterol
Familial hypercholesterolemia

CURRENT TREATMENT OPTIONS
Overview of the antidyslipidemic drug classes
Prescribing trends
Prescription trends for specific dyslipidemia subgroups are based on antidyslipidemic class efficacy
Class usage across the seven markets is largely consistent
Prescribing strategies
Therapy switching is most commonly due to insufficient lipid modulation
Generic antidyslipidemics continue to take market share from key brands following Lipitor's patent expiry

PRESCRIBING INFLUENCES AND UNMET NEEDS
Prescribing influences
(Untitled sub-section)
Treatment outcomes: unmet needs
Physicians’ highest priority unmet needs: antidyslipidemics with stronger efficacy at improving lipid deviations

BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports